The antibody levels of the third dose of our vaccine significantly exceed the levels observed after the initial two-stage scheme, the companies said in a statement.
BioNTech and Pfizer have sent preliminary data to the U.S. Food and Drug Administration (FDA) in support of using the third dose of the coronavirus vaccine. This is stated in the company’s press release distributed on Monday.
“The data obtained to date suggest that the antibody levels of the third dose of our vaccine significantly exceed the levels observed after the initial two-stage scheme. We are pleased to provide this data to the FDA as we continue to work together to address emerging issues related to the pandemic,” said Pfizer CEO Albert Bourla.
As noted, adult study participants from the United States received a booster dose of the vaccine 8-9 months after receiving the second dose. According to the results obtained, the subjects who underwent the third stage of vaccination had higher concentrations of neutralizing antibodies against the original SARS-CoV-2 virus (non-mutant type) and the beta strain and delta strain compared to those who underwent two-stage vaccination.